NBY — NovaBay Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for NovaBay Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | C2023 December 31st | C2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -5.82 | -10.6 | -9.64 | -7.22 | -22.1 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | -3.45 | 2.94 | 6.26 | 3.15 | 25.7 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.038 | 0.533 | -0.433 | -0.122 | -0.825 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -9.19 | -6.65 | -3.76 | -4.2 | 2.7 |
| Capital Expenditures | -0.052 | -0.112 | -0.019 | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -12 | 0 | 0 | — | — |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Cash from Investing Activities | -12 | -0.112 | -0.019 | — | — |
| Financing Cash Flow Items | — | — | -0.373 | — | — |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 16.8 | 4.63 | 1.54 | 1.5 | 4.62 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -4.45 | -2.13 | -2.24 | -2.7 | 7.32 |